Abstract
Monolithic lipid matrices were developed that allow parenteral drug release for days, weeks or even months. The cylindrical matrices consist of triglycerides or triglyceride/cholesterol mixtures and allow, due to their small dimensions, an application via injection. Pure triglyceride matrices showed less than 3%, triglyceride matrices containing 70% and more cholesterol less than 10% water uptake ...
Abstract
Monolithic lipid matrices were developed that allow parenteral drug release for days, weeks or even months. The cylindrical matrices consist of triglycerides or triglyceride/cholesterol mixtures and allow, due to their small dimensions, an application via injection. Pure triglyceride matrices showed less than 3%, triglyceride matrices containing 70% and more cholesterol less than 10% water uptake over 30 weeks. This swelling behavior would allow the use of such matrices even for sophisticated applications such as interstitial drug delivery to the brain where excessive swelling is highly undesirable. The drug release kinetics were found to depend strongly on the fatty acid chain length of the triglyceride and the cholesterol content of the matrices. Increasing the chain length from C-12 to C-18 allowed an increase in the release of pyranine, a low molecular weight model compound, from approx. 60 days to more than 120 days. Adding cholesterol to glyceryl trimyristate matrices made it possible to adjust the release within a time span varying from days to weeks. While matrices containing 50% cholesterol released pyranine within 8 days, cholesterol contents of 90% allowed a release of the dye for more than 3 weeks. (C) 2002 Elsevier Science B.V. All rights reserved.
Altmetric